key: cord-0966644-pamkzvrz
authors: Halwe, Sandro; Kupke, Alexandra; Vanshylla, Kanika; Liberta, Falk; Gruell, Henning; Zehner, Matthias; Rohde, Cornelius; Krähling, Verena; Gellhorn-Serra, Michelle; Kreer, Christoph; Klüver, Michael; Sauerhering, Lucie; Schmidt, Jörg; Cai, Zheng; Han, Fei; Young, David; Yang, Guangwei; Widera, Marek; Koch, Manuel; Werner, Anke; Kämper, Lennart; Becker, Nico; Marlow, Michael S; Eickmann, Markus; Ciesek, Sandra; Schiele, Felix; Klein, Florian; Becker, Stephan
title: Intranasal administration of a monoclonal neutralizing antibody protects mice against SARS-CoV-2 infection
date: 2021-06-09
journal: bioRxiv
DOI: 10.1101/2021.06.09.447662
sha: 80733e271dfa941b6afbd78a6a235d99bb5c5bc2
doc_id: 966644
cord_uid: pamkzvrz

Despite recent availability of vaccines against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), there is an urgent need for specific anti-SARS-CoV-2 drugs. Monoclonal neutralizing antibodies are an important drug class in the global fight against the SARS-CoV-2 pandemic due to their ability to convey immediate protection and their potential to be used as both, prophylactic and therapeutic drugs. Clinically used neutralizing antibodies against respiratory viruses are currently injected intravenously, which can lead to suboptimal pulmonary bioavailability and thus to a lower effectiveness. Here we describe DZIF-10c, a fully human monoclonal neutralizing antibody that binds the receptor-binding domain of SARS-CoV-2 spike protein. DZIF-10c displays an exceptionally high neutralizing potency against SARS-CoV-2 and retains activity against the variants of concern B.1.1.7 and B.1.351. Importantly, not only systemic but also intranasal application of DZIF-10c abolished presence of infectious particles in the lungs of SARS-CoV-2 infected mice and mitigated lung pathology. Along with a favorable pharmacokinetic profile, these results highlight DZIF-10c as a novel human SARS-CoV-2 neutralizing antibody with high in vitro and in vivo antiviral potency. The successful intranasal application of DZIF-10c paves the way for clinical trials investigating topical delivery of anti-SARS-CoV-2 antibodies. Significance Statement Monoclonal neutralizing antibodies are important in the global fight against the SARS-CoV-2 pandemic due to their ability to convey immediate protection. However, their intravenous application might lead to suboptimal bioavailability in the lung. We here precisely characterize a new monoclonal neutralizing antibody (DZIF-10c) that binds to the receptor binding domain of the spike protein of SARS-CoV-2. DZIF-10c neutralizes SARS-CoV-2 with exceptionally high potency and maintains activity against circulating variants of concern. The antibody has a favorable pharmacokinetic profile and protects mice from SARS-CoV-2 infection. Importantly, we show that intranasal administration of DZIF-10c generates protective efficacy. These results not only identify DZIF-10c as a novel highly potent neutralizing antibody, but further pave the way for a topical application of anti-SARS-CoV-2 antibodies.

. The reconstructed 3D cryo-EM map of 167 the analyzed Fab-antigen complex clearly shows the trimeric shape of the S protein and additional density 168 for a single DZIF-10c Fab, bound to one of the three S protein protomers ( Fig. 2A) . The reconstructed S 169 protein is arranged in a conformation showing one RBD in "up"-conformation, while the remaining two 170 RBDs reside in "down"-conformation corresponding to the prefusion conformation (31). The DZIF-10c Fab 171 fragment binds to the RBD in "up"-conformation and is arranged nearly perpendicular, relative to the 172 symmetry axis of the S protein trimer ( Fig. 2A) . No Fab density was observed close to the remaining two 173

RBDs in "down"-conformation, despite the 3:1 molar excess of Fab to S protein trimer suggesting that 174 DZIF-10c preferably binds the "up"-conformation of the RBD, which corresponds to the activated prefusion 175 state of the S protein. Furthermore, the data show that the approximated binding position and angle of 176 DZIF-10c do not or only peripherally interfere with the ACE2 binding motif on the RBD (Fig. 2B) , pointing 177 to a mode of inhibition independent from directly blocking the ACE2 binding. 178

In view of its promising in vitro properties, we next characterized the pharmacokinetic profile of DZIF-10c 180 after a single i.v. injection in two different mouse models. First, DZIF-10c was investigated in severe 181 combined immunodeficient (SCID) mice expressing a human alpha chain Fc molecule instead of the 182 endogenous mouse Fcgrt (Fig. 3A) . The human neonatal Fc receptor (huFcRn) reduces lysosomal 183 degradation of human IgG and plays a key role in antibody half-life. Mice genetically engineered to express 184 the human neonatal Fc receptor are used as a surrogate model for antibody pharmacokinetics in humans 185 (32). After administration of an antibody dose of 0.5 mg in PBS, antibody serum levels were determined 186 by a human IgG ELISA using purified human myeloma IgG as on-plate standard. In these mice, DZIF-10c 187 showed a favorable pharmacokinetic profile similar to two HIV-1-neutralizing human IgG antibodies that 188 are currently in clinical investigation and show in vivo half-life of approximately 2 weeks (3BNC117) to 3 189 weeks (10-1074) in humans(7, 33, 34). In addition, DZIF-10c was administered to immunodeficient NRG mice that do not express the IL-2 receptor common gamma chain, carry a knock-out mutation in the Rag1 191 gene, and do not develop murine lymphocytes or NK cells (Fig. 3B) . This model has previously been used 192 to faithfully reproduce the overall pharmacokinetic characteristics of antiviral antibodies in humans (6, 7, 193 34, 35) . Again, compared to the reference antibodies the pharmacokinetic profile of DZIF-10c was similar 194 or prolonged. Neither mouse model showed accelerated clearance and/or serum elimination of DZIF-10c. 195

To demonstrate the antiviral efficacy in vivo, we analyzed the prophylactic and therapeutic potential of 197 DZIF-10c after SARS-CoV-2 challenge in a hACE2 transduction mouse model. Since mice are naturally not 198 susceptible to SARS-CoV-2 infection due to incompatibility of the S protein to murine ACE2 (36-38), we 199 transduced BALB/c mice intratracheally with an adenoviral vector carrying the genetic information for 200 hACE2 and the reporter mCherry (Ad_ACE2-mCherry). This approach is based on a previously published 201 model for middle east respiratory syndrome coronavirus (MERS-CoV) and has been shown to be suitable 202 for modeling SARS-CoV-2 infection (39, 40) as well as preclinical testing of a SARS-CoV-2 vaccine candidate 203 (41). Moreover, this model was used successfully by several other groups to study SARS-CoV-2 204 pathogenesis and antiviral interventions(18, 42, 43). The recombinant adenovirus additionally encodes the 205 fluorescent protein mCherry, which allows the assessment of the transduction efficiency (Fig. S6) . First, 206

we assessed if DZIF-10c can protect hACE2-transduced mice from SARS-CoV-2 infection in a prophylactic 207 setting. To this end, we transduced BALB/c mice with Ad_ACE2-mCherry on day three prior to challenge 208 followed by a single dose of 40 mg/KG body weight DZIF-10c or an IgG isotype control antibody on day one 209 prior to challenge (Fig. 4A) . The antibodies were administered by two different routes to model a systemic 210 (i.p.) or a topical (i.n.) administration. One day after treatment, mice were challenged with SARS-CoV-2 211 and monitored daily for changes in body weight, behavior and appearance. Four days post challenge, the 212 mice were euthanized, and the lungs were collected for viral load determination as well as histological 213 analyses. Neither significant body weight changes nor clinical symptoms were observed in any of the groups (Fig. S7) , which is in line with previous reports of hACE2-transduced mice (41, 44). Importantly, 215 this result indicated that the presence of DZIF-10c did not induce antibody-dependent enhancement 216 (ADE). Regarding viral load, we observed high titers of infectious SARS-CoV-2 in lung homogenates of all 217 mice that received the IgG isotype control antibody with 2.46x10 3 (± 1.06x10 3 ) TCID 50 /25 mg tissue in the 218 i.n. group and 8.35x10 3 (± 3.76x10 3 ) TCID 50 /25 mg tissue in the i.p. group (Fig. 4B ). In contrast, no infectious 219 virus was detected in mice prophylactically treated with DZIF-10c independent on the route of delivery, 220

indicating efficient neutralization of SARS-CoV-2 in vivo. In line with these results, viral genomic RNA 221 (gRNA) measured by RT-qPCR was reduced significantly by approximately two log scales in DZIF-10c-222 treated mice (Fig. 4C ). Intriguingly, in animals receiving the antibody i.n., the decrease was approximately 223 three times greater compared to animals of the i.p. group. Because of the possibility that gRNA measured 224 by RT-qPCR is partially derived either from input virus or intact, but neutralized virions that are not yet 225 cleared by the immune system, we further analyzed subgenomic RNA (sgRNA) levels to assess active SARS-226

CoV-2 replication. Confirming the absence of infectious particles in the TCID 50 assay, sgRNA levels dropped 227 dramatically after prophylactic DZIF-10c treatment by more than three log scales in the i.n. and more than 228 two log scales in the i.p. group (Fig. 4D ). As expected, sgRNA was detected in high amounts in all control 229 mice which indicates active replication that is prevented in case of prophylactic treatment with DZIF-10c. 230

Again, we could observe a 6-fold stronger reduction of sgRNA in animals treated via the i.n. route 231 compared to i.p. application. 232

Next, we evaluated the impact of DZIF-10c on lung histopathology after hematoxylin-eosin (H&E) staining. 233

In lungs of control mice, we observed interstitial pneumonia with multiple, partially confluent foci and 234 distinct lymphohistiocytic infiltrations in the interstitium and in the perivascular space (Fig. 4E) . 235

Importantly, prophylactic treatment with DZIF-10c markedly mitigated lung pathology with all animals 236

showing only mild signs of inflammation. To quantify the histopathological findings, the overall 237 dissemination of inflammation in the lung as well as the highest severity in terms of immune cell infiltration 238 and damage to the lung architecture was assessed using a scoring system from 0 (no inflammation) to 4 239 (most severe) (Fig. S9 ). Confirming the visual observation, histopathological scores were reduced 2-fold in 240 DZIF-10c treated mice (Fig. 4F) . To compare the amounts of SARS-CoV-2 RNA, especially in inflamed areas, 241 we further visualized viral RNA using in situ hybridization with SARS-CoV-2-specific probes. Consistent with 242 our previous results, we detected high amounts of viral RNA in samples from control animals that 243 particularly concentrated in regions with inflammation ( Fig. 4E , G) whereas in DZIF-10c-treated mice, viral 244 RNA was only detectable in single cells without spread to the surrounding tissue. This difference was more 245 pronounced in i.n. treated mice as viral RNA was completely absent in three animals in this group. 246

Altogether, these findings indicate that prophylactic treatment with DZIF-10c, either administered i.p. or 247 i.n., efficiently protected hACE2-transduced mice from infection with SARS-CoV-2 as well as SARS-CoV-2-248 related lung pathology. Intriguingly, the i.n. administration of DZIF-10c seemed to be more effective than 249 systemic application. 250

To investigate the efficiency of a therapeutic treatment with DZIF-10c, we transduced BALB/c mice 251 intratracheally with Ad_ACE2-mCherry three days before the animals were infected intranasally with 252 SARS-CoV-2 (Fig. 5A ). In the therapeutic regimen, the mice received two doses of 40 mg/KG body weight 253 of DZIF-10c or the isotype control antibody on days one and three after infection, either via the i.p. or the 254 i.n. route. On day four, the animals were sacrificed and samples were taken. Clinical symptoms were 255 absent except in one mouse of the i.n. control group, which lost 7% body weight on day four (Fig. S8 ). On 256 average, 9.31x10 3 (± 3.37 x10 3 ) TCID 50 /25 mg tissue were detected in the i.n. control group and 1.66x10 4 257 (± 4.90 x10 3 ) TCID 50 /25 mg tissue in the i.p. control group (Fig. 5B ). Similar to the prophylactic regimen, no 258 infectious particles were detected in lung homogenates of DZIF-10c-treated animals indicating efficient 259 neutralization of SARS-CoV-2 after therapeutic intervention with DZIF-10c. Interestingly, SARS-CoV-2 gRNA 260 and sgRNA were only slightly reduced (2-3-fold) in animals receiving DZIF-10c compared to those receiving 261 the isotype control (Fig. 5B, C) . This observation was confirmed by in situ hybridization, which revealed a 262 slight reduction of viral RNA in lung slices, independent on the route of antibody application (Fig. 5E, G) . 263 H&E staining revealed widespread inflammation in multiple, partially confluent foci with infiltration of 264 lymphocytes and macrophages (Fig. 5E, F) . The histopathological picture did not significantly differ 265 between the DZIF-10c-treated and the control groups with a tendency towards a slight improvement after 266 DZIF-10c treatment. position, DZIF-10c belongs to class 3 binders, which are characterized by targeting a region outside of the 307 ACE2 binding motif (Fig. S5) . In contrast to the other binders in class 3, DZIF-10c is attached to the RBD 308 only in the "up"-conformation. Due to the broad variance of resolution as evident from the local resolution 309 map (Fig. S4C) , the reconstruction in the binding region (6-10 Å) did not allow for atomic or per amino acid 310 residue refinement of the coordinates. Therefore, the presented model represents only When it comes to immunotherapy against viral pathogens, another area of concern is antibody-dependent 355 enhancement of infection and disease which is based on the uptake of antibody-bound viral particles into 356

FcR-expressing cells like macrophages or dendritic cells(45, 61). To date, there is no clear evidence that 357 ADE plays a significant role in COVID-19 disease progression. Consistent with other studies (17, 62), we did 358 not observe any signs of enhanced disease after DZIF-10c treatment in our mouse model (Fig. S7-S8) . 359

Furthermore, an in vitro ADE assay did not indicate that DZIF-10c leads to enhanced infection in FcR-360 bearing human macrophages. Although susceptibility of CD14 + human macrophages to SARS-CoV-2 may 361 be limited, this suggests that ADE-related adverse effects of DZIF-10c are not very likely to appear in clinical 362 trials in humans. 363

In summary, we characterized a novel fully human SARS-CoV-2 neutralizing antibody, DZIF-10c, which 364 exhibited an extraordinary neutralizing potency comparable with some of the most potent anti-SARS-CoV-365 2 nAbs available to date. We further demonstrated that prophylactic treatment with DZIF-10c protects 366 hACE2-transduced mice from infection with SARS-CoV-2. Moreover, our data indicate that topical 367 administration of DZIF-10c may be a suitable delivery route that could be advantageous in clinical use. The 368 results presented in this study made a decisive contribution to DZIF-10c having entered a phase I/II clinical 369 trial that, for the first time, investigates an inhaled administration of a nAb targeting SARS-CoV-2 370 (NCT04631705). 371 carbon copper grid (Electron Microscopy Sciences) that had been freshly glow-discharged for 1 min at 20 419 mA using a PELCO easiGLOW (Ted Pella). Samples were vitrified in 100% liquid ethane using a Leica EM 420 GP2 automatic plunge freezer (Leica Microsystems) after blotting at 10 °C and 85% humidity for 4 s. cryo-421 EM images were collected on a Titan Krios transmission electron microscope (Thermo Fisher) at 300 kV 422 using a K3 detector (Gatan) in super-resolution counting mode. Images were energy filtered (20 eV slit) 423 and collected automatically using EPU v. 1.2 software (Thermo Fisher). Each image was composed of 50 424 individual frames with a total exposure dose of 50 e -/Ų and a pixel size of 0.415 Å. Single particle data 425 processing was performed in cryoSPARC v2.15 (Structura Biotechnology Inc.) as described below. Super 426 resolution movies were patch motion corrected, Fourier-cropped (factor 1/2) and dose weighted before 427 estimating CTF parameters using the Patch CTF job type. Particles were picked using the reference-free Blob picker, extracted with a box size of 360 pixels (0.83 Å/pixel) and subjected to 2D classification. The 429 best class averages were selected manually (226k particles) to create an ab initio 3D model followed by a 430 homogeneous refinement. Particles were then 3D-classified into four classes and the best resolved classes 431 were selected for a final round of homogenous and subsequent non-uniform refinement (142k particles). 432 In order to quantify viral gRNA, nucleic acids were isolated from cell lysates or lung homogenates using 447 the RNeasy Mini Kit (Qiagen) according to manufacturer's instructions. Total RNA amount was measured 448 using a NanoDrop ND-100 spectrophotometer. 449

For analysis of SARS-CoV-2 genome copies, RNA was reverse transcribed and viral genome copies 450 quantified by real-time PCR using the OneStep RT-PCR Kit (Qiagen) and the StepOne Real-Time PCR System 451 (Applied Biosystems). Primers and probes targeting the E gene of SARS-CoV-2 (E Assay_First Line Application of monoclonal antibodies (DZIF-10c or IgG isotype control) was performed via the intranasal 524 or the intraperitoneal route at a dose of 40 mg/KG. Antibody treatment was conducted on day one before 525 infection (prophylactic regimen) or twice on day one and three after infection (therapeutic regimen). In 526 order to ensure a safe administration of antibodies, mice were anesthetized shortly with isoflurane before 527 each treatment. 528

Lungs were collected on day four post challenge with SARS-CoV-2 and processed for histological analysis 530 as described before (40). Tissue was fixed in formalin and embedded in paraffin. For histopathological 531 analysis, sections were cut with a Leica RM2255 microtome (Leica Biosystems) and stained with 532 hematoxylin and eosin (H&E). To investigate the presence of viral RNA, lungs were mounted on slides and 533 analyzed via in-situ hybridization. To this end, the RNAscope® 2.5 HD Assay -RED Kit from Bio-Techne (Cat. 534

No. 322360) was used according to the manufacturer's instructions. Briefly, mounted slides were baked at 535 60°C, deparaffinized with xylene and 100% ethanol and pretreated with RNAscope® Pretreatment 536 Reagents (Cat. No. 322300 and 322000) to enable access to the target RNA. Subsequently, a RNA-specific 537 probe, targeted against the S gene of the SARS-CoV-2 (Cat. No. 848561), was hybridized to the RNA. Fast 538

Red substrate was administered to the samples, allowing signal detection. The slides were counterstained 539 with Gill's Hematoxylin I and 0.02 % ammonia water. A RNAscope® Negative Control Probe (Cat. No. 540 310043) was used in parallel to monitor background staining. 541

In order to test for statistical differences in viral load analyses (RT-qPCR, TCID 50 assays) and 543 histopathological scores between treated and non-treated animals, a nonparametric analysis using the 544 Mann-Whitney test was performed. Results were declared significant at p < 0.05. All statistical analyses 545 were performed using GraphPad Prism.

COVID-19 United States Cases by County

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. The New England 550 journal of medicine

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: 552 an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. The New England 555 journal of medicine

Reduction of Respiratory Syncytial Virus (RSV) in Tracheal Aspirates in Intubated 557 Infants by Use of Humanized Monoclonal Antibody to RSV F Protein

HIV therapy by a combination of broadly neutralizing antibodies in humanized mice

Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody

3BNC117

Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp

Controlled Trial of Ebola Virus Disease Therapeutics

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a 568 Clinically Proven Protease Inhibitor

SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies

Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody 572 cocktail

REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques 574 and hamsters

REGN-COV2, a Neutralizing Antibody Cocktail

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on

Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial

A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 583 spike protein

A SARS-CoV-2 Infection Model in Mice Demonstrates Protection by Neutralizing

Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline

Challenges and opportunities for antiviral monoclonal antibodies as COVID-19

Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies 591 from COVID-19 Patients

Evaluation of Heavy-Chain C-Terminal Deletion on Product Quality and 593 Pharmacokinetics of Monoclonal Antibodies

Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV

Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2. 598 bioRxiv

SARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-elicited, convalescent and 600 monoclonal antibodies. medRxiv : the preprint server for health sciences

SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor 603 plasma. Nature medicine

Bamlanivimab does not neutralize two SARS-CoV-2 variants carrying E484K in vitro

Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7. Nature

Immunodominant SARS Coronavirus Epitopes in Humans Elicited both Enhancing and 609

Neutralizing Effects on Infection in Non-human Primates

Structures and distributions of SARS-CoV-2 spike proteins on intact virions

Humanized FcRn mouse models for evaluating pharmacokinetics of 615 human IgG antibodies

Restriction of HIV-1 Escape by a Highly Broad and Potent Neutralizing Antibody

Antibody 10-1074 suppresses viremia in HIV-1-infected individuals

HIV-1 suppression and durable control by combining single broadly neutralizing 621 antibodies and antiretroviral drugs in humanized mice

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Receptor Recognition by the Novel Coronavirus from

Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus

The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice

Protective Efficacy of Recombinant Modified Vaccinia Virus Ankara Delivering Middle

East Respiratory Syndrome Coronavirus Spike Glycoprotein

A Highly Immunogenic and Protective Middle East Respiratory Syndrome 632

Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine Platform

Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA SARS 635 2 S in preclinical vaccination

A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection

Generation of a Broadly Useful Model for COVID-19 Pathogenesis, Vaccination, and 639 Treatment

Comparison of transgenic and adenovirus hACE2 mouse models for SARS-CoV-641 2 infection

Anti-severe acute respiratory syndrome coronavirus spike antibodies trigger 643 infection of human immune cells via a pH-and cysteine protease-independent FcγR pathway

Active replication of Middle East respiratory syndrome coronavirus and aberrant 646 induction of inflammatory cytokines and chemokines in human macrophages: implications for 647 pathogenesis

Differential cell line susceptibility to the emerging novel human betacoronavirus 649 2c EMC/2012: implications for disease pathogenesis and clinical manifestation. The Journal of 650 infectious diseases

Tropism, replication competence, and innate immune responses of the coronavirus

SARS-CoV-2 in human respiratory tract and conjunctiva: an analysis in ex-vivo and in-vitro cultures

Antibody-dependent enhancement and SARS-CoV

Monocytes and macrophages, targets of SARS-CoV-2: the clue for Covid-19

The Journal of infectious diseases

DNA vaccine protection against SARS-CoV-2 in rhesus macaques

Virological assessment of hospitalized patients with COVID-2019

Comparison of Subgenomic and Total RNA in SARS-CoV-2 Challenged Rhesus

Journal of virology

Animal models of mechanisms of SARS-CoV-2 infection and COVID-19 pathology

Animal models for COVID-19

Direct administration in the respiratory 668 tract improves efficacy of broadly neutralizing anti-influenza virus monoclonal antibodies

Effectiveness of topically 671 administered neutralizing antibodies in experimental immunotherapy of respiratory syncytial virus 672 infection in cotton rats

Intranasal monoclonal IgA antibody to respiratory syncytial virus protects rhesus 674 monkeys against upper and lower respiratory tract infection

Therapeutic activity of an inhaled potent SARS-CoV-2 neutralizing human 677 monoclonal antibody in hamsters

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

A perspective on potential antibody-dependent enhancement of SARS-CoV-2

An engineered receptor-binding domain improves the immunogenicity of 683 multivalent SARS-CoV-2 vaccines. bioRxiv : the preprint server for biology

Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the 686 UK defined by a novel set of spike mutations

Emergence and rapid spread of a new severe acute respiratory syndrome-related 688 coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa

Development and characterization of an indirect ELISA to detect SARS-CoV-2 spike 691 protein-specific antibodies

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-693 2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Virus isolation and quantitation

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro 698 surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease 699 bulletin

Detection of a novel human coronavirus by real-time reverse-transcription 701 polymerase chain reaction. Euro surveillance : bulletin Europeen sur les maladies transmissibles = 702

Cyclophilin inhibitors restrict Middle East respiratory syndrome coronavirus via 704 interferon-λ in vitro and in mice

Philipp Mengel and Nadine Biedenkopf for the help with 709 sequencing of virus isolates and Tobias Nolden for his support with the cloning of expression plasmids for 710 the pseudovirus variants. We acknowledge Christian Keller and the European Virus Archive Global (EVAg) 711 for providing virus isolates used in this study

Prill and Julia Eppensteiner for excellent technical support

This work was funded by the German Center for Infection Research, the BMBF initiative 716 "NaFoUniMedCovid19" (FKZ: 01KX2021, subprojects B-FAST and COVIM) and the Loewe Research Center

addition, the work was supported by two grants from the von-Behring-Röntgen-Stiftung to AK 718 and SB

Data and materials availability

All relevant data are within the manuscript and its Supporting Information files. Materials/samples used 721 in the analysis described in this manuscript may be made available to qualified, academic, 722 noncommercial researchers through a material transfer agreement upon request

A) Interaction of DZIF-10c, REGN10933 and REGN10987 with SARS-CoV-2 S RBD measured by ELISA. (B) Neutralizing 725 activity of DZIF-10c against SARS-CoV-2 pseudoviruses bearing S proteins from different circulating strains. The 726 dotted line indicates 50% neutralization (IC 50 ). (C) Neutralization of authentic SARS-CoV-2

Circles represent geometric means of four independent experiments. Lines and error bars 729 indicate the overall mean with SEM. (D) Summary of the neutralizing activity

CoV-2 pseudoviruses bearing various mutations in the S protein as well as against authentic SARS-CoV-2

A) Cryo-EM map with S protein colored in gray shades (according to three protomers), density corresponding to the 733 RBDs colored in cyan shades and density corresponding to the Fab fragment colored in yellow. left: side view; right: 734 top view. (B) Approximate binding position and angle of DZIF

RBD (PDB-6XDG) colored in grey and receptor binding motif (RBM) on RBD colored in red

A) Pharmacokinetic profile of DZIF-10c and two human anti-HIV-1 IgG1 antibodies in mice expressing the human 738 neonatal Fc receptor after i.v. injection of a 0.5 mg dose. (B) Pharmacokinetic profile of DZIF-10c and two human 739 anti-HIV-1 IgG1 antibodies in NRG mice after i.v. injection of a 0.5 mg dose

Viral load and histological analysis of hACE2-transduced BALB/c mice prophylactically treated with DZIF-10c 742 (A) Study plan of the prophylactic dose regimen. BALB/c mice were transduced with Ad_ACE2-mCherry three days 743 before infection and treated i.n. or i.p. with 40 mg/KG body weight DZIF-10c or an IgG control antibody one day prior 744 to challenge with SARS-CoV-2

Two mice from the i.n. control group had to be excluded from the analysis due to insufficient transduction efficiency

Infectious SARS-CoV-2 titer in lung homogenates on day four post infection determined by TCID 50 assay

SARS-CoV-2 gRNA and sgRNA in lung homogenates on day four post infection determined by RT-qPCR. Error bars 748 represent mean ± SEM. Statistical analyses were performed using Graph Pad Prism and Mann-Whitney test

Dotted lines indicate the lower limit of detection. (E) Histopathological analysis of the lungs by 750 H&E staining and in situ hybridization of viral RNA. Images were acquired at a magnification of 40x or 100x

Quantification of histopathological scores for dissemination and highest severity of inflammation as well as 752 dissemination of viral RNA. Error bars represent mean ± SEM. Statistical analyses were performed using Graph Pad 753 Prism and Mann-Whitney test

Study plan of the therapeutic dose regimen. BALB/c mice were transduced with Ad_ACE2-mCherry three days 756 before challenge with SARS-CoV-2. Mice were treated i.n. or i.p. with 40 mg/KG body weight DZIF-10c or an IgG 757 control antibody on days one and three post infection. On day four post infection, the animals were euthanized and 758 samples were collected. (B) Infectious SARS-CoV-2 titer in lung homogenates on day four post infection determined 759 by TCID 50 assay. (C-D) SARS-CoV-2 gRNA and sgRNA in lung homogenates on day four post infection determined by 760 RT-qPCR

Dotted lines indicate the lower limit of detection. (E) Histopathological analysis 762 of the lungs by H&E staining and in situ hybridization of viral RNA. Images were acquired at a magnification of 40x or 763 100x. (F-G) Quantification of histopathological scores for dissemination and highest severity of inflammation as well 764 as dissemination of viral RNA. Error bars represent mean ± SEM. Statistical analyses were performed using Graph Pad 765 Prism and Mann-Whitney test

DMEM with ceramic and glass beads (Lysing Matrix H 500, 2 ml tube, MP Biomedicals) in a mixer mill 520 (Retsch Schwingmühle MM 400) for 5 min at 30 Hz. To remove tissue debris, homogenates were 521 centrifuged for 5 min at 2,400 rpm. 40 µl of fresh homogenates were used for a TCID 50 assay. Further 100 522 µl of the homogenate were used for RNA isolation.